脑回状浸润作为分子胶质母细胞瘤的影像生物标志物
本研究评估脑回状浸润(MRI FLAIR序列上皮质高信号)对分子胶质母细胞瘤的诊断价值,纳入426例新诊断胶质瘤患者。
要点
- 脑回状浸润在16/31(52%)分子胶质母细胞瘤中观察到,在IDH突变型胶质瘤中均未观察到。
- 所有56例脑回状浸润阳性肿瘤均为IDH野生型,除2例外均有TERT启动子突变。
- 脑回状浸润阴性患者的中位总生存期优于阳性患者(25.6 vs 16.9个月,p=0.005)。
核心结论
- 脑回状浸润是分子胶质母细胞瘤的特异性影像标志物,可帮助将其与IDH突变型低级别胶质瘤区分。
研究设计与样本
- 回顾性分析新诊断胶质瘤患者的MRI扫描,由两名独立研究者评估脑回状浸润(定义为MRI FLAIR序列上 elective 皮质高信号)的存在。
- 共纳入426例患者,包括31例分子胶质母细胞瘤、294例IDH野生型胶质母细胞瘤、50例IDH突变型星形细胞瘤和51例IDH突变型1p19q共缺失少突胶质细胞瘤。
主要发现
- 脑回状浸润在16/31(52%)分子胶质母细胞瘤、40/294(14%)IDH野生型胶质母细胞瘤中观察到,在IDH突变型胶质瘤中均未观察到。
- 所有56例脑回状浸润阳性肿瘤均为IDH野生型,除2例外均有TERT启动子突变。
- 评估者间一致性良好(κ=0.69,p<0.001)。
- 脑回状浸润诊断分子胶质母细胞瘤的敏感度、特异度、阳性预测值和阴性预测值分别为52%、90%、29%、96%。
- 在全系列和 non-enhancing 病变患者(n=95)中,脑回状浸润阴性患者的中位总生存期优于阳性患者(25.6 vs 16.9个月,p=0.005;20.2个月 vs 未达到,p<0.001)。
关键数值与推荐
- 脑回状浸润定义为MRI FLAIR序列上 elective 皮质高信号。
- 脑回状浸润诊断分子胶质母细胞瘤的敏感度52%、特异度90%、阳性预测值29%、阴性预测值96%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular glioblastomas (i.e. without the histological but with the molecular characteristics of IDH-wild-type glioblastoma) frequently lack contrast enhancement, which can wrongly lead to suspect a lower-grade glioma. Herein, we aimed to assess the diagnostic value of gyriform infiltration as an imaging marker for molecular glioblastomas. METHODS: Two independent investigators reviewed the MRI scans from patients with newly diagnosed gliomas for the presence of a gyriform infiltration defined as an elective cortical hypersignal on MRI FLAIR sequence. Diagnostic test performance of this sign for the diagnosis of molecular glioblastoma were calculated. RESULTS: A total of 426 patients were included, corresponding to 31 molecular glioblastoma, 294 IDH-wild-type glioblastoma, 50 IDH-mutant astrocytoma, and 51 IDH-mutant 1p19q-codeleted oligodendroglioma. A gyriform infiltration was observed in 16/31 (52%) molecular glioblastoma, 40/294 (14%) IDH-wild-type glioblastoma, and none of the IDH-mutant glioma. All the 56 gyriform-infiltration-positive tumors were IDH-wild-type and all but two had a TERT promoter mutation. The inter-rater agreement was good (κ = 0.69, p < 0.001). The sensitivity, specificity, positive predictive value and negative predictive value of the presence of a gyriform infiltration for the diagnosis of molecular glioblastoma were 52%, 90%, 29%, 96%, respectively. The median overall survival was better for gyriform-infiltration-negative patients compared to gyriform-infiltration-positive patients in the whole series and in patients with non-enhancing lesions (n = 95) (25.6 vs 16.9 months, p = 0.005 and 20.2 months vs not reached, p < 0.001). CONCLUSION: Gyriform infiltration is a specific imaging marker of molecular glioblastomas that can help distinguishing these tumors from IDH-mutant lower-grade gliomas.
引用
- Mesny E, Barritault M, Izquierdo C, et al. Gyriform infiltration as imaging biomarker for molecular glioblastomas. J Neurooncol. 2022. PMID: 35364762. doi:10.1007/s11060-022-03995-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。